Ion channel

Sodium channels are tiny gates in nerve cell membranes that open briefly to let sodium ions rush in, sending an electrical signal down the cell. They are the fundamental triggers of every nerve impulse, muscle contraction, and heartbeat.

Your body uses nine different sodium channel types, each coded by its own gene. They are named Nav1.1 through Nav1.9. The evidence here focuses mostly on channels in sensory nerves that detect pain (dorsal root ganglia and trigeminal ganglia). In human pain-sensing neurons, one subtype called Nav1.9 makes up a meaningful fraction of the total sodium current. Its behavior differs depending on where the nerve cell lives. In trigeminal ganglion neurons (which sense the face), Nav1.9 inactivates at a more positive voltage than it does in spinal dorsal root ganglion neurons [1]. That rightward shift creates a larger "window current" — a trickle of steady sodium entry that makes the nerve easier to excite [1]. The trigeminal channel also activates faster and recovers more slowly from inactivation, meaning it is readier to fire but stays altered longer after a stimulus [1].

Multiple studies confirm that these channels are not static. After a nerve injury in rats, the mix of subtypes on damaged sensory neurons shifts dramatically: the normal slow-inactivating Nav1.8 and Nav1.9 channels drop by factors of 20 to 30, while the fast-inactivating fetal-type Nav1.3 channel rises 4-fold [4]. That molecular switch remodels the firing properties of the injured nerve cell, explaining part of how neuropathic pain becomes chronic. A similar pattern appears in epilepsy. After prolonged seizures in rats, hippocampal neurons re-express neonatal sodium channel isoforms, and the window current triples in size — from 64 pA to 217 pA median [2]. A larger standing sodium current makes the neuron permanently hyperexcitable.

A new 2026 study on human sensory neurons found that an inflammatory soup (prostaglandin, histamine, serotonin, and bradykinin) significantly potentiates Nav1.9 currents and shifts their activation voltage by about 14 mV toward the resting potential [1]. This means pain signals are amplified at the site of inflammation. The same study tested two experimental blockers and found TC-N1752 inhibited human Nav1.9 with an IC50 of 0.26 µM and ICA604025 with an IC50 of 0.56 µM [1].

Other substances also affect sodium channels directly. The paracetamol metabolite AM404 inhibits Nav1.7 and Nav1.8 with remarkable potency — IC50 values of 22 nM and 55 nM respectively at near-resting membrane potentials — by binding to the same site as local anesthetics [5]. This explains why paracetamol works on nerve pain but the parent drug has no effect on sodium channels [5]. Plant cannabinoids like CBD and CBG also block sodium currents, but a 2014 study using mouse cortical neurons found that this block does not correlate with anticonvulsant effects in vivo [3], meaning the seizure protection from CBD comes through a different mechanism.

My call: the evidence base here is rich for basic science but thin on clinical trials. The mechanistic picture is clear — these channels drive excitability in pain and epilepsy circuits — but no completed human trials testing specific sodium channel blockers against hard clinical outcomes are included in this retrieval. For a patient asking whether a particular sodium channel drug is worth taking, the burden of proof has not been met by the evidence here. Confidence: moderate for the basic mechanisms, low for clinical utility against real-world pain or epilepsy endpoints.